{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:01:34Z","timestamp":1775318494982,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmogo.2026.100312","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:52:36Z","timestamp":1773132756000},"page":"100312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fruquintinib in combination with tislelizumab versus trifluridine\/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases\u2014the IKF-080\/AIO-QUINTIS trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-9433","authenticated-orcid":false,"given":"J.","family":"Tintelnot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gorgulho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-E.","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-599X","authenticated-orcid":false,"given":"D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Reinacher-Schick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Boston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9768-0086","authenticated-orcid":false,"given":"A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.esmogo.2026.100312_bib1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9863","key":"10.1016\/j.esmogo.2026.100312_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.esmogo.2026.100312_bib3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"10395","key":"10.1016\/j.esmogo.2026.100312_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2026.100312_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2025.43.4_suppl.127","article-title":"Zanzalintinib (XL092) alone or in combination with atezolizumab in patients (pts) with refractory metastatic colorectal cancer (mCRC): results from an expansion cohort of the phase 1 STELLAR-001 study","volume":"43","author":"Fontana","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100312_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100312_bib7","first-page":"849","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal randomised, controlled trial","volume":"20","author":"Eng","year":"2019"},{"issue":"24","key":"10.1016\/j.esmogo.2026.100312_bib8","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2026.100312_bib9","article-title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: the phase 3, randomized KEYFORM-007 study","volume":"43","author":"Segal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100312_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10517","key":"10.1016\/j.esmogo.2026.100312_bib11","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100312_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100312_bib13","doi-asserted-by":"crossref","first-page":"754881","DOI":"10.3389\/fonc.2021.754881","article-title":"Efficacy and safety of fruquintinib plus PD-1 inhibitors versus regorafenib plus PD-1 inhibitors in refractory microsatellite stable metastatic colorectal cancer.","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmogo.2026.100312_bib14","doi-asserted-by":"crossref","first-page":"851756","DOI":"10.3389\/fonc.2022.851756","article-title":"Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H\/pMMR metastatic colorectal cancer: a real-world study in China.","volume":"12","author":"Gou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmogo.2026.100312_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2026.100312_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.2023.41.4_suppl.150","article-title":"Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): results from the FRUIT trial","volume":"41","author":"Yuan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100312_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14737140.2025.2474736","article-title":"Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100312_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-24-0561","article-title":"Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted therapy and immunotherapy","volume":"13","author":"Tintelnot","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"7950","key":"10.1016\/j.esmogo.2026.100312_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","article-title":"Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer","volume":"615","author":"Tintelnot","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.esmogo.2026.100312_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002844","article-title":"PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer","volume":"9","author":"Stein","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100312_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006678","article-title":"First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial","volume":"11","author":"Paschold","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmogo.2026.100312_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.993611","article-title":"Translational analysis and final efficacy of the AVETUX trial \u2013 avelumab, cetuximab and FOLFOX in metastatic colorectal cancer","volume":"12","author":"Tintelnot","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100312_bib23","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","article-title":"Early ctDNA and survival in metastatic colorectal cancer treated with immune checkpoint inhibitors: a secondary analysis of the SAMCO-PRODIGE 54 randomized clinical trial","volume":"11","author":"Ta\u00efeb","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100312_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41573-025-01211-7","article-title":"The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development","volume":"24","author":"Elkrief","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100312_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006633","article-title":"Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study","volume":"11","author":"Moretto","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100312_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102945","article-title":"Impact of KRASG12 mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial","volume":"9","author":"Tabernero","year":"2024","journal-title":"ESMO open"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:05:41Z","timestamp":1775315141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"alternative-id":["S2949819826000129"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100312","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fruquintinib in combination with tislelizumab versus trifluridine\/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases\u2014the IKF-080\/AIO-QUINTIS trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100312"}}